Home » News » Drug Sponsors » Shire to buy Advanced BioHealing

Shire to buy Advanced BioHealing

Wednesday, May 18, 2011

Ireland-based Shire will acquire the U.S.-based Advanced BioHealing for $750 million in cash, according to Pharma Times.

Shire’s interest is in Advanced BioHealing’s Dermograft, a regenerative bio-engineered skin substitute used for the treatment of diabetic foot ulcers. Shire says Dermagraft has a “favorable reimbursement profile,” notably with Medicare (100% coverage), and that generic products “would have to overcome high regulatory, development and manufacturing hurdles” to enter the DFU market.

Advanced BioHealing also has fully enrolled multinational trials to investigate Dermagraft to treat venous leg ulcers.

Mike Cola, president of Shire’s specialty pharmaceuticals business, said the acquisition is “a strong and complementary strategic fit.” He claimed that “the potential to build on the success of Dermagraft is attractive” as it provides a solution for a common complication suffered by diabetics that, “if not treated effectively, can lead to lower limb amputation and high cost to patients and society.”

Looking for more news, check out the new FREE CenterWatch Weekly!

The new FREE CenterWatch Weekly is your source of critical news, emerging trends, and business issues around everything in the rapidly changing clinical research marketplace. Check out our new CWWeekly page! Sign up today for your free email newsletter, update your bookmarks and check us out regularly! We look forward to bringing you the best news and information about clinical research in 2018!